Drug intelligence / Profile preview

SY-101

Development stage: Preclinical
Lead developer: Seinda Pharmaceutical

Overview

SY-101 is an investigational drug candidate being developed by Seinda (Seinda Biomedical) for the treatment of myopia. As of early 2024, the program is in the preclinical and IND-enabling stages of development. While Seinda has not publicly disclosed the specific modality, molecular target, or mechanism of action for SY-101, it is a key component of the company's ophthalmic pipeline, which focuses on innovative therapies for vision-related conditions. The development of SY-101 aims to address the growing global prevalence of myopia through pharmacological intervention.

Beyond the preview

Go deeper on SY-101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SY-101.

Explore the full profile